Terms: = Leukemia AND MYH11, ENSG00000133392, 4629 AND Prognosis
104 results:
1. KIT exon 17 mutations are predictive of inferior outcome in pediatric acute myeloid leukemia with RUNX1::RUNX1T1.
Srinivasan S; Dhamne C; Patkar N; Chatterjee G; Moulik NR; Chichra A; Pallath A; Tembhare P; Shetty D; Subramanian PG; Narula G; Banavali S
Pediatr Blood Cancer; 2024 Feb; 71(2):e30791. PubMed ID: 38014874
[TBL] [Abstract] [Full Text] [Related]
2. [Clinical features and prognosis of core binding factor acute myeloid leukemia children in South China: a multicenter study].
Guo BY; Wang Y; Li J; Li CF; Feng XQ; Zheng MC; Liu SX; Yang LH; Jiang H; Xu HG; He XL; Wen H
Zhonghua Er Ke Za Zhi; 2023 Oct; 61(10):881-888. PubMed ID: 37803854
[No Abstract] [Full Text] [Related]
3. Core-binding factor abnormalities involving chromosome 16 in acute myeloid leukaemia: prognostic and therapeutic implications.
Panigrahi C; Tikare N; Das PK; Padhi S
BMJ Case Rep; 2023 Aug; 16(8):. PubMed ID: 37591621
[TBL] [Abstract] [Full Text] [Related]
4. CAG (cytarabine, aclarubicin and granulocyte colony-stimulating factor) regimen for core binding factor acute myeloid leukaemia with measurable residual disease.
Shen YJ; Zhang Y; Chang J; Wang HF; Ye XN; Zhu L; Jin J; Zhu HH
Ann Hematol; 2023 Jul; 102(7):1731-1738. PubMed ID: 37145324
[TBL] [Abstract] [Full Text] [Related]
5. RNA sequencing of myeloid sarcoma, shed light on myeloid sarcoma stratification.
Yang Y; Shu Y; Tang Y; Zhao S; Jia Y; Ji J; Ma H; Lin T; Zheng K; Xu H; Wu Y
Cancer Med; 2023 Apr; 12(8):9156-9166. PubMed ID: 36916780
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive molecular understanding of pediatric acute myeloid leukemia.
Shiba N
Int J Hematol; 2023 Feb; 117(2):173-181. PubMed ID: 36653696
[TBL] [Abstract] [Full Text] [Related]
7. Transcriptome-based molecular subtypes and differentiation hierarchies improve the classification framework of acute myeloid leukemia.
Cheng WY; Li JF; Zhu YM; Lin XJ; Wen LJ; Zhang F; Zhang YL; Zhao M; Fang H; Wang SY; Lin XJ; Qiao N; Yin W; Zhang JN; Dai YT; Jiang L; Sun XJ; Xu Y; Zhang TT; Chen SN; Zhu HH; Chen Z; Jin J; Wu DP; Shen Y; Chen SJ
Proc Natl Acad Sci U S A; 2022 Dec; 119(49):e2211429119. PubMed ID: 36442087
[TBL] [Abstract] [Full Text] [Related]
8. AML with inv(16)/t(16;16) and high-risk cytogenetic abnormalities: atypical features and unfavorable outcome.
Assaf N; Lefebvre C; Raggueneau V; Guignedoux G; Marceau-Renaut A; Chevalier S; Tondeur S; Bories D; Benramdane R; Rousselot P; Terré C
Hematology; 2022 Dec; 27(1):636-641. PubMed ID: 35622005
[TBL] [Abstract] [Full Text] [Related]
9. Jumping translocation involving chromosome 13q in a patient with Crohn's Disease and inv(16)(p13.1q22)/CBFB-myh11 acute myeloid leukemia.
Clarke S; de Kraa R; Chuah H; Creeper K; Leahy MF; Wright M
Cancer Genet; 2022 Aug; 266-267():7-14. PubMed ID: 35613501
[TBL] [Abstract] [Full Text] [Related]
10. [Clinical Characteristics and prognosis of Acute Myeloid leukemia Patients with inv(16)/t(16;16)(p13.1;q22) and/or CBFβ-myh11].
Wang YM; Cai P; Zhou MJ; Gong YY; Pan JL; Cen JN; Yang XF; Chen SN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):. PubMed ID: 35400360
[TBL] [Abstract] [Full Text] [Related]
11. [Clinical Characteristics and prognosis of Acute Myeloid leukemia Patients with inv(16)/t(16;16)(p13.1;q22) and/or CBFβ-myh11].
Wang YM; Cai P; Zhou MJ; Gong YY; Pan JL; Cen JN; Yang XF; Chen SN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):367-372. PubMed ID: 35395965
[TBL] [Abstract] [Full Text] [Related]
12. Rare type I CBFβ/myh11 fusion transcript in primary acute myeloid leukemia with inv(16)(p13.1q22): a case report.
Zhang W; Wang H; Zhang P; Li H; Ma X; Liu H
Braz J Med Biol Res; 2021; 54(12):e11605. PubMed ID: 34730684
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic of Core Binding Factor (CBF) Acute Myeloid leukemia With Complex Karyotype.
Marcault C; Boissel N; Haferlach C; Loschi M; Raynaud S; Cluzeau T
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):e199-e205. PubMed ID: 34674982
[TBL] [Abstract] [Full Text] [Related]
14. [Prognostic value of KIT and other clonal genetic mutations in core-binding factor acute myeloid leukemia].
Wu TM; Xue SL; Li Z; Yu JQ; Wang J; Wang BR; Wan CL; Shen XD; Qiu QC; Bao XB; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2021 Aug; 42(8):646-653. PubMed ID: 34547870
[No Abstract] [Full Text] [Related]
15. Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells.
Owen N; Minko IG; Moellmer SA; Cammann SK; Lloyd RS; McCullough AK
Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836581
[TBL] [Abstract] [Full Text] [Related]
16. [The Prognostic Factors for AML Children with CBFβ/myh11 Positive].
Yan M; Song FX; Lu J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):369-373. PubMed ID: 33812401
[TBL] [Abstract] [Full Text] [Related]
17. Both the subtypes of KIT mutation and minimal residual disease are associated with prognosis in core binding factor acute myeloid leukemia: a retrospective clinical cohort study in single center.
Duan W; Liu X; Zhao X; Jia J; Wang J; Gong L; Jiang Q; Zhao T; Wang Y; Zhang X; Xu L; Shi H; Chang Y; Liu K; Huang X; Qin Y; Jiang H
Ann Hematol; 2021 May; 100(5):1203-1212. PubMed ID: 33474629
[TBL] [Abstract] [Full Text] [Related]
18. [Prognostic Value of CD123 in Acute Myeloid leukemia Patients with Intermediate Risk in Normal Karyotype].
Zhang Y; Liu RY; Wang SJ; Wang C; Zhang QT; He C; Xie XS; Wan DM; Jiang ZX; Liu YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1880-1884. PubMed ID: 33283714
[TBL] [Abstract] [Full Text] [Related]
19. [Clinical significance of MRD in AML].
Ishikawa Y
Rinsho Ketsueki; 2020; 61(9):1150-1159. PubMed ID: 33162510
[TBL] [Abstract] [Full Text] [Related]
20. [Clinical features and prognosis of core binding factor acute myeloid leukemia in children].
Liu C; Chen XY; Yi MH; Wu WQ; Ruan M; Zhu XF
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Jul; 22(7):739-743. PubMed ID: 32669171
[TBL] [Abstract] [Full Text] [Related]
[Next]
